PITTSBURGH, May 5 The University of Pittsburgh Cancer Institute (UPCI) today announced the establishment of the Frieda G. and Saul F. Shapira BRCA Cancer Research Program. BRCA 1 and 2 are two genes that, when mutated, dramatically increase the risk of breast, prostate, ovarian and pancreatic cancers.
I am excited about the addition of this research program to UPCI, said Ronald Herberman, M.D., director of UPCI and the University of Pittsburgh Medical Center (UPMC) Cancer Centers. The more we learn about these mutations, the better chance we have to target high-risk patients and to find innovative ways to reduce their cancer risk.
Women who possess either mutation have a 50 to 80 percent lifetime risk of developing breast cancer, and the disease progresses more quickly than in individuals without the mutations. Experts estimate that as many as one out of every 345 people in the U.S. carries a BRCA mutation, but for individuals of Ashkenazi (Eastern European) Jewish descent, the number is approximately one in 40.
These mutations have been linked primarily with an increased risk of breast cancer in women, but they also increase the risk for other cancers. Both men and women can carry the genetic mutations, which means they can be passed to children from either parent.
The David S. and Karen A. Shapira Foundation committed an initial $1 million for the program, structuring the gift as a matching grant to raise an additional $1.5 million from individuals and foundations. UPMC is matching these gifts on a dollar-for-dollar basis, for an overall goal of $5 million.
Currently, the burden of cancer costs each American approximately $936 a year, said Dr. Herberman. The National Cancer Institutes budget supporting research amounts to only $21 per American annually. To fund promising cancer research, researchers need other means of support. A gift like the one we have received from the Shapira Foundation, complemented by fun
|Contact: Courtney McCrimmon|
University of Pittsburgh Medical Center